These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12077887)

  • 21. [Be careful on the Internet].
    Jensen JW
    Ugeskr Laeger; 2006 Sep; 168(38):3189. PubMed ID: 17026889
    [No Abstract]   [Full Text] [Related]  

  • 22. EU directive on clinical trials penalizes small sponsors.
    Meldolesi A
    Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
    [No Abstract]   [Full Text] [Related]  

  • 23. [Increased commercial financing of national Medical Product Agencies within the EU].
    Ramel B
    Lakartidningen; 2003 Jan; 100(5):338-9. PubMed ID: 12607381
    [No Abstract]   [Full Text] [Related]  

  • 24. Europe's opportunity to open up drug regulation.
    Garattini S; Bertele' V
    BMJ; 2010 Mar; 340():c1578. PubMed ID: 20354022
    [No Abstract]   [Full Text] [Related]  

  • 25. [Organization of the Federal Drug and Medical Products Institute in view of increased European competition].
    Kurth R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Mar; 51(3):340-4. PubMed ID: 18369569
    [No Abstract]   [Full Text] [Related]  

  • 26. Unfair competition under the TRIPS agreement: protection of data submitted for the registration of pharmaceuticals.
    Correa CM
    Chic J Int Law; 2002; 3(1):69-85. PubMed ID: 15709300
    [No Abstract]   [Full Text] [Related]  

  • 27. [The Medical Product Agency's work and economics--a comment].
    Ahlqvist Rastad J; Salmonson T
    Lakartidningen; 2003 Jan; 100(5):345. PubMed ID: 12607382
    [No Abstract]   [Full Text] [Related]  

  • 28. The World Health Organization's prequalification program and its potential effect on data exclusivity laws.
    Childs DW
    Food Drug Law J; 2005; 60(1):79-97. PubMed ID: 15940855
    [No Abstract]   [Full Text] [Related]  

  • 29. [Editorial Letter. Drug approval].
    Borvendég J
    Neuropsychopharmacol Hung; 2011 Jun; 13(2):54-5. PubMed ID: 21919287
    [No Abstract]   [Full Text] [Related]  

  • 30. [Marketing authorization for pharmaceuticals: the necessity of European collaboration].
    Seitz R; Enzmann H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):703-4. PubMed ID: 18592336
    [No Abstract]   [Full Text] [Related]  

  • 31. [Two years with EMEA: towards a unified drug registration within the EEC].
    Lennholm B
    Lakartidningen; 1997 Jan; 94(1-2):8-12. PubMed ID: 9053613
    [No Abstract]   [Full Text] [Related]  

  • 32. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Walking the drug regulatory tightrope.
    Dove A
    Nat Biotechnol; 2003 May; 21(5):495-8. PubMed ID: 12721571
    [No Abstract]   [Full Text] [Related]  

  • 34. Data and market exclusivity for pharmaceuticals in the European Community.
    Kingham RF; Castle GH
    Food Drug Law J; 2000; 55(2):209-23. PubMed ID: 12269365
    [No Abstract]   [Full Text] [Related]  

  • 35. Equivocal role of micelles in Eprex adverse events.
    Smiell JM
    Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595347
    [No Abstract]   [Full Text] [Related]  

  • 36. Equivocal role of micelles in Eprex adverse events.
    Schellekens H; Crommelin DJ
    Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595346
    [No Abstract]   [Full Text] [Related]  

  • 37. EMEA approves OGS drug rejected by FDA.
    Mitchell P
    Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
    [No Abstract]   [Full Text] [Related]  

  • 38. Changing standards for drug approval: A longitudinal analysis of conditional marketing authorisation in the European Union.
    Hoekman J; Boon W
    Soc Sci Med; 2019 Feb; 222():76-83. PubMed ID: 30605802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tysabri back on market.
    Sheridan C
    Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
    [No Abstract]   [Full Text] [Related]  

  • 40. [The role of the Danish Medical Products Agency in clinical trials].
    Simonsen AC
    Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.